Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Carriers | 17 | 2026 | 174 | 4.630 |
Why?
|
| Nanoparticles | 18 | 2025 | 460 | 3.930 |
Why?
|
| Nanostructures | 9 | 2026 | 161 | 3.190 |
Why?
|
| Polymers | 6 | 2025 | 155 | 2.110 |
Why?
|
| Drug Delivery Systems | 12 | 2026 | 277 | 2.100 |
Why?
|
| Antineoplastic Agents | 13 | 2018 | 1019 | 1.910 |
Why?
|
| Lipids | 6 | 2026 | 256 | 1.820 |
Why?
|
| Lung Neoplasms | 12 | 2018 | 495 | 1.810 |
Why?
|
| RNA, Small Interfering | 5 | 2018 | 436 | 1.740 |
Why?
|
| Particle Size | 21 | 2026 | 272 | 1.670 |
Why?
|
| Noscapine | 6 | 2016 | 17 | 1.640 |
Why?
|
| Liposomes | 8 | 2025 | 132 | 1.560 |
Why?
|
| Chemistry, Pharmaceutical | 13 | 2026 | 97 | 1.510 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2017 | 133 | 1.110 |
Why?
|
| Neoplasms | 6 | 2022 | 1377 | 1.100 |
Why?
|
| Nanocapsules | 3 | 2017 | 19 | 1.080 |
Why?
|
| Powders | 9 | 2019 | 20 | 1.060 |
Why?
|
| Lung | 7 | 2019 | 492 | 1.010 |
Why?
|
| Chitosan | 2 | 2025 | 53 | 0.990 |
Why?
|
| Lactoferrin | 1 | 2026 | 9 | 0.970 |
Why?
|
| Quinolones | 1 | 2026 | 14 | 0.970 |
Why?
|
| Thiophenes | 1 | 2026 | 32 | 0.950 |
Why?
|
| Sulfasalazine | 1 | 2025 | 1 | 0.930 |
Why?
|
| Albumins | 1 | 2025 | 33 | 0.920 |
Why?
|
| Guanidines | 1 | 2025 | 17 | 0.920 |
Why?
|
| Thalidomide | 1 | 2025 | 6 | 0.920 |
Why?
|
| Psoriasis | 1 | 2025 | 19 | 0.910 |
Why?
|
| Hydrogels | 2 | 2025 | 59 | 0.900 |
Why?
|
| Aerosols | 8 | 2017 | 54 | 0.880 |
Why?
|
| Thiazoles | 1 | 2025 | 76 | 0.880 |
Why?
|
| Delayed-Action Preparations | 5 | 2025 | 74 | 0.870 |
Why?
|
| Deoxycytidine | 2 | 2017 | 38 | 0.850 |
Why?
|
| Nebulizers and Vaporizers | 4 | 2025 | 22 | 0.810 |
Why?
|
| Drug Compounding | 8 | 2025 | 93 | 0.800 |
Why?
|
| Administration, Inhalation | 11 | 2025 | 92 | 0.800 |
Why?
|
| Antiviral Agents | 1 | 2025 | 195 | 0.780 |
Why?
|
| Biopharmaceutics | 1 | 2022 | 2 | 0.780 |
Why?
|
| Nanomedicine | 4 | 2022 | 52 | 0.770 |
Why?
|
| Brain | 4 | 2026 | 1472 | 0.730 |
Why?
|
| Cell Survival | 7 | 2025 | 945 | 0.710 |
Why?
|
| Biocompatible Materials | 1 | 2022 | 108 | 0.700 |
Why?
|
| Polyethylene Glycols | 4 | 2025 | 108 | 0.680 |
Why?
|
| Cell Line, Tumor | 13 | 2025 | 2676 | 0.670 |
Why?
|
| Animals | 32 | 2026 | 16992 | 0.660 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2019 | 62 | 0.600 |
Why?
|
| Humans | 41 | 2025 | 43102 | 0.600 |
Why?
|
| Ethers | 1 | 2018 | 21 | 0.570 |
Why?
|
| Freeze Drying | 4 | 2021 | 29 | 0.540 |
Why?
|
| Alzheimer Disease | 3 | 2020 | 1001 | 0.520 |
Why?
|
| Antitussive Agents | 2 | 2014 | 7 | 0.520 |
Why?
|
| Acrylamide | 1 | 2016 | 8 | 0.510 |
Why?
|
| Benzofurans | 1 | 2016 | 22 | 0.500 |
Why?
|
| Arginine | 1 | 2016 | 75 | 0.490 |
Why?
|
| Solubility | 6 | 2026 | 139 | 0.480 |
Why?
|
| Plant Preparations | 1 | 2016 | 24 | 0.470 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 53 | 0.460 |
Why?
|
| Drug Synergism | 6 | 2016 | 195 | 0.450 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2016 | 347 | 0.440 |
Why?
|
| Drug Discovery | 1 | 2016 | 108 | 0.440 |
Why?
|
| Mannose | 2 | 2016 | 32 | 0.430 |
Why?
|
| Intestinal Absorption | 1 | 2014 | 22 | 0.430 |
Why?
|
| Mice | 15 | 2025 | 6644 | 0.420 |
Why?
|
| STAT6 Transcription Factor | 1 | 2013 | 17 | 0.410 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 139 | 0.410 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 49 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 220 | 0.390 |
Why?
|
| Mesothelioma | 1 | 2014 | 148 | 0.380 |
Why?
|
| Nanotechnology | 6 | 2022 | 176 | 0.380 |
Why?
|
| Excipients | 2 | 2025 | 25 | 0.370 |
Why?
|
| Pharmaceutical Preparations | 4 | 2015 | 94 | 0.360 |
Why?
|
| Selenium | 1 | 2013 | 155 | 0.350 |
Why?
|
| Cisplatin | 2 | 2016 | 98 | 0.340 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 291 | 0.340 |
Why?
|
| Oxidation-Reduction | 2 | 2025 | 457 | 0.330 |
Why?
|
| Doxorubicin | 1 | 2011 | 97 | 0.320 |
Why?
|
| Apoptosis | 5 | 2011 | 1568 | 0.320 |
Why?
|
| MicroRNAs | 1 | 2014 | 518 | 0.280 |
Why?
|
| Dapsone | 1 | 2008 | 2 | 0.280 |
Why?
|
| Tacrolimus | 1 | 2007 | 16 | 0.260 |
Why?
|
| Amiloride | 1 | 2006 | 19 | 0.250 |
Why?
|
| Indoles | 4 | 2014 | 187 | 0.240 |
Why?
|
| Biological Availability | 6 | 2018 | 116 | 0.240 |
Why?
|
| Mice, Nude | 6 | 2014 | 408 | 0.240 |
Why?
|
| Surface-Active Agents | 1 | 2026 | 46 | 0.240 |
Why?
|
| Benzamidines | 1 | 2025 | 5 | 0.230 |
Why?
|
| Gelatin | 2 | 2017 | 17 | 0.230 |
Why?
|
| Esters | 1 | 2025 | 25 | 0.230 |
Why?
|
| Glycerides | 1 | 2025 | 12 | 0.230 |
Why?
|
| Vero Cells | 1 | 2025 | 112 | 0.220 |
Why?
|
| Cells, Cultured | 3 | 2014 | 1621 | 0.220 |
Why?
|
| Glutathione | 1 | 2025 | 171 | 0.220 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2016 | 388 | 0.210 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2025 | 146 | 0.210 |
Why?
|
| Tissue Distribution | 4 | 2019 | 240 | 0.200 |
Why?
|
| Caspase 3 | 4 | 2011 | 227 | 0.200 |
Why?
|
| Rats | 7 | 2019 | 3735 | 0.190 |
Why?
|
| Computer Simulation | 1 | 2025 | 408 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 30 | 0.190 |
Why?
|
| Nanocomposites | 1 | 2022 | 22 | 0.190 |
Why?
|
| Heparin | 1 | 2022 | 40 | 0.180 |
Why?
|
| Virus Diseases | 1 | 2021 | 27 | 0.170 |
Why?
|
| Biological Transport | 2 | 2018 | 204 | 0.170 |
Why?
|
| Technology, Pharmaceutical | 3 | 2017 | 35 | 0.170 |
Why?
|
| Taxoids | 2 | 2013 | 50 | 0.170 |
Why?
|
| X-Ray Diffraction | 2 | 2018 | 66 | 0.170 |
Why?
|
| DNA Fragmentation | 2 | 2011 | 98 | 0.160 |
Why?
|
| RNA-Binding Proteins | 1 | 2022 | 161 | 0.160 |
Why?
|
| RNA | 1 | 2022 | 266 | 0.160 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 3 | 0.150 |
Why?
|
| Blood-Brain Barrier | 2 | 2018 | 173 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2011 | 161 | 0.150 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1723 | 0.150 |
Why?
|
| Methylcellulose | 1 | 2018 | 7 | 0.150 |
Why?
|
| Nifedipine | 1 | 2018 | 10 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2018 | 1455 | 0.150 |
Why?
|
| Calcium Channel Blockers | 1 | 2018 | 55 | 0.140 |
Why?
|
| Rhodamines | 1 | 2018 | 22 | 0.140 |
Why?
|
| Nose | 1 | 2018 | 11 | 0.140 |
Why?
|
| Tablets | 1 | 2017 | 14 | 0.130 |
Why?
|
| Desiccation | 2 | 2008 | 10 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2019 | 232 | 0.130 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2017 | 35 | 0.130 |
Why?
|
| Viscosity | 1 | 2017 | 46 | 0.130 |
Why?
|
| Etoposide | 1 | 2016 | 21 | 0.130 |
Why?
|
| Caco-2 Cells | 2 | 2014 | 64 | 0.130 |
Why?
|
| Metabolic Clearance Rate | 2 | 2007 | 30 | 0.130 |
Why?
|
| Dendrimers | 1 | 2015 | 15 | 0.120 |
Why?
|
| Plants, Medicinal | 1 | 2016 | 57 | 0.120 |
Why?
|
| Phytotherapy | 1 | 2016 | 75 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2013 | 103 | 0.110 |
Why?
|
| Skin Diseases | 1 | 2015 | 30 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2013 | 91 | 0.110 |
Why?
|
| Receptor, EphA2 | 1 | 2014 | 6 | 0.110 |
Why?
|
| Powder Diffraction | 1 | 2013 | 2 | 0.100 |
Why?
|
| RNA Stability | 1 | 2013 | 28 | 0.100 |
Why?
|
| Dogs | 1 | 2014 | 204 | 0.100 |
Why?
|
| Molecular Weight | 1 | 2013 | 168 | 0.100 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2013 | 104 | 0.100 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 53 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 455 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2013 | 27 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 638 | 0.100 |
Why?
|
| Porosity | 2 | 2022 | 43 | 0.090 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 465 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 25 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2014 | 1766 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 114 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 77 | 0.090 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 10 | 0.090 |
Why?
|
| Female | 8 | 2013 | 24698 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2019 | 260 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 183 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2015 | 502 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 883 | 0.080 |
Why?
|
| Amikacin | 1 | 2009 | 3 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 934 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2011 | 358 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 968 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2019 | 159 | 0.070 |
Why?
|
| Emulsions | 2 | 2019 | 36 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 127 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2007 | 14 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2008 | 75 | 0.060 |
Why?
|
| Rheology | 1 | 2007 | 51 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 259 | 0.060 |
Why?
|
| Sodium Channel Blockers | 1 | 2006 | 18 | 0.060 |
Why?
|
| Materials Testing | 1 | 2007 | 101 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2014 | 694 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 134 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 94 | 0.060 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2006 | 4 | 0.060 |
Why?
|
| Clobetasol | 1 | 2005 | 1 | 0.060 |
Why?
|
| Eczema | 1 | 2005 | 5 | 0.060 |
Why?
|
| Amphotericin B | 1 | 2005 | 25 | 0.060 |
Why?
|
| Mycoses | 1 | 2005 | 31 | 0.060 |
Why?
|
| Skin | 1 | 2005 | 187 | 0.050 |
Why?
|
| Crystallization | 2 | 2018 | 88 | 0.050 |
Why?
|
| Silicon Dioxide | 1 | 2022 | 39 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2022 | 9 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 112 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 144 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 2157 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 122 | 0.040 |
Why?
|
| Acrylic Resins | 1 | 2019 | 13 | 0.040 |
Why?
|
| Goats | 1 | 2019 | 23 | 0.040 |
Why?
|
| Metronidazole | 1 | 2019 | 16 | 0.040 |
Why?
|
| Diffusion | 1 | 2019 | 63 | 0.040 |
Why?
|
| Hyaluronic Acid | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cellulose | 1 | 2019 | 24 | 0.040 |
Why?
|
| Alginates | 1 | 2019 | 20 | 0.040 |
Why?
|
| Microspheres | 1 | 2019 | 49 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 87 | 0.040 |
Why?
|
| Visual Acuity | 1 | 2019 | 111 | 0.040 |
Why?
|
| Drug Storage | 1 | 2018 | 28 | 0.040 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2018 | 83 | 0.040 |
Why?
|
| Surface Properties | 1 | 2019 | 160 | 0.040 |
Why?
|
| Galantamine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mucociliary Clearance | 1 | 2018 | 5 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 5 | 0.040 |
Why?
|
| Deferoxamine | 1 | 2018 | 17 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2018 | 35 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2009 | 79 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2018 | 89 | 0.030 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 32 | 0.030 |
Why?
|
| Olfactory Bulb | 1 | 2018 | 50 | 0.030 |
Why?
|
| Models, Biological | 2 | 2012 | 712 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2017 | 9 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 1857 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1869 | 0.030 |
Why?
|
| Water | 1 | 2018 | 316 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 151 | 0.030 |
Why?
|
| Drug Stability | 1 | 2016 | 129 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2015 | 16 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2015 | 48 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2014 | 55 | 0.030 |
Why?
|
| Endocytosis | 1 | 2014 | 118 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2013 | 109 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 307 | 0.020 |
Why?
|
| Ligands | 1 | 2014 | 388 | 0.020 |
Why?
|
| Male | 4 | 2019 | 23409 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 67 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 67 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1082 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 575 | 0.020 |
Why?
|
| Dosage Forms | 1 | 2010 | 4 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1596 | 0.020 |
Why?
|
| Capsules | 1 | 2009 | 28 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 129 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2010 | 259 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2008 | 76 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 152 | 0.020 |
Why?
|
| Tobramycin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Mathematical Computing | 1 | 2006 | 9 | 0.020 |
Why?
|
| Poloxamer | 1 | 2006 | 13 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 228 | 0.010 |
Why?
|
| Leucine | 1 | 2006 | 31 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 8214 | 0.010 |
Why?
|
| Micelles | 1 | 2005 | 36 | 0.010 |
Why?
|
| Cadaver | 1 | 2005 | 40 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2006 | 204 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2005 | 317 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2005 | 245 | 0.010 |
Why?
|
| Temperature | 1 | 2005 | 313 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1124 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 758 | 0.010 |
Why?
|